<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29777102</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.</ArticleTitle><Pagination><StartPage>94</StartPage><MedlinePgn>94</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">94</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41426-018-0094-1</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD) is an infectious disease that mainly affects infants and children, causing considerable morbidity and mortality worldwide. HFMD is commonly caused by enterovirus 71 (EV71) and coxsackieviruses A16 (CVA16), A6 (CVA6), and A10 (CVA10). Formalin-inactivated EV71 vaccines are currently available in China; however, these vaccines fail to confer cross-protection against infections by other HFMD-causing enteroviruses, highlighting the necessity of developing a multivalent HFMD vaccine. Our previous studies demonstrated that recombinant virus-like particles (VLP) of EV71, CVA16, and CVA6 are capable of inducing protective immunity against homologous virus challenges in mice. In this study, we generated CVA10-VLP using a baculovirus-insect cell expression system and then combined CVA10-VLP with EV71-VLP, CVA16-VLP, and CVA6-VLP to formulate a tetravalent VLP vaccine. Immunogenicity and protective efficacy of tetravalent VLP vaccine was compared with that of monovalent VLP vaccines. Mouse immunization studies revealed that the tetravalent vaccine elicited antigen-specific and long-lasting serum antibody responses comparable to those elicited by its corresponding monovalent vaccines. Moreover, tetravalent vaccine immune sera strongly neutralized EV71, CVA16, CVA10, and CVA6 strains with neutralization titers similar to those of their monovalent counterparts, indicating a good compatibility among the four antigens in the combination vaccine. Importantly, passively transferred tetravalent vaccine-immunized sera conferred efficient protection against single or mixed infections with EV71, CVA16, CVA10, and CVA6 viruses in mice, whereas the monovalent vaccines could only protect mice against homotypic virus infections but not heterotypic challenges. These results demonstrate that the tetravalent VLP vaccine represents a promising broad-spectrum HFMD vaccine candidate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, CAS Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Wenlong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, CAS Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, CAS Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, CAS Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Pei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, CAS Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shuxia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, CAS Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Xiaohua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, CAS Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qingwei</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, CAS Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China. qwliu@ips.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Dongming</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, CAS Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China. dmzhou@ips.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, CAS Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China. huangzhong@ips.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056738" MajorTopicYN="N">Cross Protection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061987" MajorTopicYN="N">Sf9 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018411" MajorTopicYN="N">Spodoptera</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29777102</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pii">10.1038/s41426-018-0094-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Repass GL, Palmer WC, Stancampiano FF. Hand, foot, and mouth disease: identifying and managing an acute viral syndrome. Clevel. Clin. J. Med. 2014;81:537&#x2013;543. doi: 10.3949/ccjm.81a.13132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.81a.13132</ArticleId><ArticleId IdType="pubmed">25183845</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventarola D, Bordone L, Silverberg N. Update on hand-foot-and-mouth disease. Clin. Dermatol. 2015;33:340&#x2013;346. doi: 10.1016/j.clindermatol.2014.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clindermatol.2014.12.011</ArticleId><ArticleId IdType="pubmed">25889136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SS, Yip CC, Lau SK, Yuen KY. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol. Infect. 2010;138:1071&#x2013;1089. doi: 10.1017/S0950268809991555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268809991555</ArticleId><ArticleId IdType="pubmed">20056019</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum. Vaccines Immunother. 2014;10:360&#x2013;367. doi: 10.4161/hv.27087.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.27087</ArticleId><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L, et al. Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide. Expert Rev. Anti Infect. Ther. 2015;13:1061&#x2013;1071. doi: 10.1586/14787210.2015.1058156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.2015.1058156</ArticleId><ArticleId IdType="pubmed">26112307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu QB, et al. Circulation of coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009-2011. PLoS One. 2012;7:e52073. doi: 10.1371/journal.pone.0052073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052073</ArticleId><ArticleId IdType="pmc">PMC3525556</ArticleId><ArticleId IdType="pubmed">23272213</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomqvist S, et al. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J. Clin. Virol. 2010;48:49&#x2013;54. doi: 10.1016/j.jcv.2010.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2010.02.002</ArticleId><ArticleId IdType="pubmed">20189452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A, et al. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin. Microbiol. Infect. 2012;18:E110&#x2013;E118. doi: 10.1111/j.1469-0691.2012.03789.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03789.x</ArticleId><ArticleId IdType="pubmed">22404077</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A, et al. Ambulatory pediatric surveillance of hand, foot and mouth disease as signal of an outbreak of coxsackievirus A6 infections, France, 2014&#x2013;2015. Emerg. Infect. Dis. 2016;22:1884&#x2013;1893. doi: 10.3201/eid2211.160590.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2211.160590</ArticleId><ArticleId IdType="pmc">PMC5088007</ArticleId><ArticleId IdType="pubmed">27767012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int. J. Infect. Dis. 2010;14:e1076&#x2013;e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi M, et al. Clinical manifestations of coxsackievirus A6 infection associated with a major outbreak of hand, foot, and mouth disease in Japan. Jpn J. Infect. Dis. 2013;66:260&#x2013;261. doi: 10.7883/yoken.66.260.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.66.260</ArticleId><ArticleId IdType="pubmed">23698493</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto A, et al. An outbreak of hand-foot-and-mouth disease mimicking chicken pox, with a frequent association of onychomadesis in Japan in 2009: a new phenotype caused by coxsackievirus A6. Eur. J. Dermatol. 2014;24:103&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">24334231</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes M, et al. Hand, foot, and mouth disease outbreak and coxsackievirus A6, northern Spain, 2011. Emerg. Infect. Dis. 2013;19:676&#x2013;678. doi: 10.3201/eid1904.121589.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1904.121589</ArticleId><ArticleId IdType="pmc">PMC3647425</ArticleId><ArticleId IdType="pubmed">23751014</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, et al. Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012. Emerg. Infect. Dis. 2013;19:641&#x2013;643. doi: 10.3201/eid1904.121666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1904.121666</ArticleId><ArticleId IdType="pmc">PMC3647428</ArticleId><ArticleId IdType="pubmed">23631943</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, et al. Hand, foot, and mouth disease outbreak caused by coxsackievirus A6, China, 2013. J. Infect. 2014;69:303&#x2013;305. doi: 10.1016/j.jinf.2014.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2014.03.015</ArticleId><ArticleId IdType="pubmed">24704297</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei SH, et al. An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect. Dis. 2011;11:346. doi: 10.1186/1471-2334-11-346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-11-346</ArticleId><ArticleId IdType="pmc">PMC3297538</ArticleId><ArticleId IdType="pubmed">22168544</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, et al. Neurologic complications in children with enterovirus 71 infection. N. Engl. J. Med. 1999;341:936&#x2013;942. doi: 10.1056/NEJM199909233411302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411302</ArticleId><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TC, et al. Diseases caused by enterovirus 71 infection. Pediatr. Infect. Dis. J. 2009;28:904&#x2013;910. doi: 10.1097/INF.0b013e3181a41d63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181a41d63</ArticleId><ArticleId IdType="pubmed">20118685</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuschino ME, et al. Detection of coxsackievirus A10 in multiple tissues of a fatal infant sepsis case. J. Clin. Virol. 2012;53:259&#x2013;261. doi: 10.1016/j.jcv.2011.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.12.011</ArticleId><ArticleId IdType="pubmed">22209288</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CY, et al. Fatal coxsackievirus A16 infection. Pediatr. Infect. Dis. J. 2004;23:275&#x2013;276. doi: 10.1097/01.inf.0000115950.63906.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000115950.63906.78</ArticleId><ArticleId IdType="pubmed">15014311</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, et al. Severe hand, foot, and mouth disease and coxsackievirus A6-Shenzhen, China. Clin. Infect. Dis. 2014;59:1504&#x2013;1505. doi: 10.1093/cid/ciu624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu624</ArticleId><ArticleId IdType="pubmed">25091307</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein M, Chong P. Is a multivalent hand, foot, and mouth disease vaccine feasible? Hum. Vaccines Immunother. 2015;11:2688&#x2013;2704. doi: 10.1080/21645515.2015.1049780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1049780</ArticleId><ArticleId IdType="pmc">PMC4685682</ArticleId><ArticleId IdType="pubmed">26009802</ArticleId></ArticleIdList></Reference><Reference><Citation>Aswathyraj S, Arunkumar G, Alidjinou EK, Hober D. Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy. Med. Microbiol. Immunol. 2016;205:397&#x2013;407. doi: 10.1007/s00430-016-0465-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-016-0465-y</ArticleId><ArticleId IdType="pubmed">27406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi EJ, et al. Enterovirus 71 infection and vaccines. Clin. Exp. Vaccin. Res. 2017;6:4&#x2013;14. doi: 10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, et al. Active immunization with a coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine. 2013;31:2215&#x2013;2221. doi: 10.1016/j.vaccine.2013.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.007</ArticleId><ArticleId IdType="pubmed">23499596</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, et al. Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections. Vaccine. 2016;34:4025&#x2013;4031. doi: 10.1016/j.vaccine.2016.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.06.028</ArticleId><ArticleId IdType="pubmed">27340093</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, et al. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine. 2016;34:5005&#x2013;5012. doi: 10.1016/j.vaccine.2016.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.08.033</ArticleId><ArticleId IdType="pubmed">27562093</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012;30:6642&#x2013;6648. doi: 10.1016/j.vaccine.2012.08.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.08.071</ArticleId><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Tong X, Huang Z. Towards broadly protective polyvalent vaccines against hand, foot and mouth disease. Microbes Infect. 2015;17:155&#x2013;162. doi: 10.1016/j.micinf.2014.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2014.11.004</ArticleId><ArticleId IdType="pubmed">25449959</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein MH. EV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccines. Expert Rev. Vaccines. 2015;14:337&#x2013;340. doi: 10.1586/14760584.2015.993385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2015.993385</ArticleId><ArticleId IdType="pubmed">25536888</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldao A, et al. Virus-like particles in vaccine development. Expert Rev. Vaccines. 2010;9:1149&#x2013;1176. doi: 10.1586/erv.10.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.10.115</ArticleId><ArticleId IdType="pubmed">20923267</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31:58&#x2013;83. doi: 10.1016/j.vaccine.2012.10.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.083</ArticleId><ArticleId IdType="pmc">PMC7115575</ArticleId><ArticleId IdType="pubmed">23142589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014;32:4296&#x2013;4303. doi: 10.1016/j.vaccine.2014.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.06.025</ArticleId><ArticleId IdType="pubmed">24950363</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, et al. Expression, purification and characterization of enterovirus-71 virus-like particles. World J. Gastroenterol. 2006;12:921&#x2013;927. doi: 10.3748/wjg.v12.i6.921.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i6.921</ArticleId><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong M, et al. Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development. J. Virol. 2014;88:6444&#x2013;6452. doi: 10.1128/JVI.00200-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00200-14</ArticleId><ArticleId IdType="pmc">PMC4093858</ArticleId><ArticleId IdType="pubmed">24672036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8:e57601. doi: 10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Wang JC, Taylor MW, Zlotnick A. In vitro assembly of an empty picornavirus capsid follows a dodecahedral path. J. Virol. 2012;86:13062&#x2013;13069. doi: 10.1128/JVI.01033-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01033-12</ArticleId><ArticleId IdType="pmc">PMC3497625</ArticleId><ArticleId IdType="pubmed">23015694</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33:2335&#x2013;2341. doi: 10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, et al. Efficacy of a trivalent hand, foot, and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in mice. Viruses. 2015;7:5919&#x2013;5932. doi: 10.3390/v7112916.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7112916</ArticleId><ArticleId IdType="pmc">PMC4664989</ArticleId><ArticleId IdType="pubmed">26593938</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, et al. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antivir. Res. 2016;129:58&#x2013;66. doi: 10.1016/j.antiviral.2016.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.02.008</ArticleId><ArticleId IdType="pubmed">26899790</ArticleId></ArticleIdList></Reference><Reference><Citation>Coller BA, Clements DE. Dengue vaccines: progress and challenges. Curr. Opin. Immunol. 2011;23:391&#x2013;398. doi: 10.1016/j.coi.2011.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2011.03.005</ArticleId><ArticleId IdType="pubmed">21514129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chokephaibulkit K, Perng GC. Challenges for the formulation of a universal vaccine against dengue. Exp. Biol. Med. (Maywood) 2013;238:566&#x2013;578. doi: 10.1177/1535370212473703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370212473703</ArticleId><ArticleId IdType="pubmed">23856907</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30:1305&#x2013;1312. doi: 10.1016/j.vaccine.2011.12.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855&#x2013;1862. doi: 10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Shi J, Liu Q, Huang Z. Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71. J. Virol. Methods. 2012;186:193&#x2013;197. doi: 10.1016/j.jviromet.2012.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.06.025</ArticleId><ArticleId IdType="pubmed">22771741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, et al. Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antivir. Res. 2016;132:165&#x2013;169. doi: 10.1016/j.antiviral.2016.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.06.004</ArticleId><ArticleId IdType="pubmed">27315772</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 1938;27:493&#x2013;497. doi: 10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, et al. Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins. J. Virol. Methods. 2011;173:115&#x2013;120. doi: 10.1016/j.jviromet.2011.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2011.01.016</ArticleId><ArticleId IdType="pubmed">21295614</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>